CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This research focuses on using engineered T cells for cancer treatment, specifically targeting hard-to-treat cancers like oesophago-gastric cancer. The project aims to conduct clinical trials to evaluate the effectiveness of this innovative therapy in improving patient outcomes.
The aim of this research is to exploit technology for nucleic acid delivery through the clinical testing of adoptive engineered T cells to treat cancer.
Recent innovative developments in cancer gene-immunotherapy have led to very encouraging early clinical results.
However, the use of engineered T cells is a challenging and complex field with further development and more proof-of-principle trials needed.
This proposal builds upon previous EU funded pre-clinical projects and comprises a multidisc…
THE UNIVERSITY OF MANCHESTER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Rotterdam
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Sweden, Stockholm
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, Manchester
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
